Surface modified targeted nanostructured lipid carrier system for Axitinib: development and characterization

In the current study, we created a new hyaluronated cationic nanostructured lipid carrier (CNLCs) that targets the CD44 biomarker, which typically overexpresses in breast cancer, and includes Axitinib (AXT). The cationic core NLCs was developed by Emulsification solvent evaporation with low temperature solidification technique consisting compritol 888 ATO and capmul MCM as mix lipid phase with 136.9± 0.7 nm particles size and 89± 0.78 % Efficiency of entrapment. Hyaluronic acid has been introduced to the cationic core NLCs via electrostatic attraction method. Hyaluronated CNLCs' particle size has grown to 327.8± 1.3 nm. Drug release experiments performed in vitro showed a initial bust release for first 2 hrs and then sustained release. The coating was further confirmed with Transmission electron microscopy (TEM) and FTIR analysis. Differential scanning calorimetry was performed to analyse crystalline behaviour of drug in formulation. Cell line study revealed that developed Surface modified NLC is targeted only to cancer cell and is nontoxic to the normal cell.